Simplify Asset Management Inc. Buys New Position in Oculis Holding AG $OCS

Simplify Asset Management Inc. bought a new stake in Oculis Holding AG (NASDAQ:OCS) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 98,765 shares of the company’s stock, valued at approximately $1,972,000.

A number of other large investors have also recently made changes to their positions in the company. Gildi lifeyrissjodur acquired a new stake in shares of Oculis in the 4th quarter valued at about $50,250,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the period. Aberdeen Group plc boosted its position in shares of Oculis by 39.4% in the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after purchasing an additional 493,827 shares during the period. Compagnie Lombard Odier SCmA raised its stake in Oculis by 10.6% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company’s stock valued at $2,143,000 after acquiring an additional 10,300 shares during the last quarter. Finally, Syquant Capital Sas acquired a new stake in Oculis during the 4th quarter worth approximately $3,849,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Price Performance

OCS opened at $29.49 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The business has a 50 day simple moving average of $27.48 and a 200-day simple moving average of $24.90. The stock has a market capitalization of $1.71 billion, a P/E ratio of -13.85 and a beta of 0.38. Oculis Holding AG has a 12 month low of $16.00 and a 12 month high of $34.47.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. On average, equities analysts anticipate that Oculis Holding AG will post -2.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. HC Wainwright increased their price objective on Oculis from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. JPMorgan Chase & Co. increased their price objective on Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a research report on Monday, May 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Needham & Company LLC increased their price objective on Oculis from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $49.38.

Oculis Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.